Drugs / Qizhi Weitong Granules
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03149393 | Feb 2017 → Dec 2020 | dyspepsia | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05113888 | Dec 2021 → Aug 2022 | irritable bowel syndrome | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qizhi Weitong Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03149393 ↗ |
| Route | Oral | “take orally before meals” NCT05113888 ↗ |